Chandrashekhar Y, Alexander T, Mullasari A, Kumbhani DJ, Alam S, Alexanderson E et al (2020) Resource and infrastructure-appropriate management of ST-segment elevation myocardial infarction in low-and middle-income countries. Circulation 141 24:2004–2025
Ito H (2006) No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3 9:499–506
Pantea-Roșan LR, Pantea VA, Bungau S, Tit DM, Behl T, Vesa CM et al (2020) No-reflow after PPCI—a predictor of short-term outcomes in STEMI patients. J Clin Med 9:9:2956
Fajar JK, Heriansyah T, Rohman MS (2018) The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J 70:S406–S418
Article PubMed PubMed Central Google Scholar
Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G (2022) No-reflow phenomenon: a contemporary review. J Clin Med 11(8):2233
Article CAS PubMed PubMed Central Google Scholar
Çınar T, Şaylık F, Hayıroğlu Mİ, Asal S, Selçuk M, Çiçek V et al (2023) The association of serum uric acid/albumin ratio with no-reflow in patients with ST elevation myocardial infarction. Angiology 74 4:381–386
Sökmen E, Ateş MS (2025) Usefulness of platelet mass index in the prediction of angiographic no-reflow in patients with acute ST-segment elevation myocardial infarction. BMC Cardiovasc Disord 25 1:1–8
Liu H, Zhang F, Li Y, Liu L, Song X, Wang J et al (2025) The HALP score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis 36 4:273–280
Heldin CH, Lennartsson J, Westermark B (2018) Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med 283(1):16–44
Article CAS PubMed Google Scholar
Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15(4):237–254
Article CAS PubMed Google Scholar
Pang S, Tao Z, Min X, Zhou C, Pan D, Cao Z et al (2020) Correlation between the serum platelet-derived growth factor, angiopoietin-1, and severity of coronary heart disease. Cardiology Research and Practice 2020
Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European society of cardiology (ESC). Eur Heart J 44 38:3720–3826
Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40(2):87–165
Levi Y, Sultan A, Alemayehu M, Wall S, Lavi S (2016) Association of endothelial dysfunction and no-reflow during primary percutaneous coronary intervention for ST-elevation myocardial infarction. Cardiovasc Revasc Med 17(8):552–555
Huyut MA, Yamac AH (2021) Outcomes in coronary no-reflow phenomenon patients and the relationship between kidney injury molecule-1 and coronary no-reflow phenomenon. Arq Bras Cardiol 116(2):238–247
Article CAS PubMed PubMed Central Google Scholar
Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A et al (2005) C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci U S A 102 40:14452–14457
Wallace JM, Freeburn JC, Gilmore WS, Sinnamon DG, Craig BM, McNally RJ et al (1998) The assessment of platelet derived growth factor concentration in post myocardial infarction and stable angina patients. Ann Clin Biochem 35(Pt 2):236–241
Koizumi T, Komiyama N, Nishimura S (2015) In-vivo higher plasma levels of Platelet-Derived growth factor and matrix Metalloproteinase-9 in coronary artery at the very onset of myocardial infarction with ST-segment elevation. Ann Vasc Dis 8(4):297–301
Article PubMed PubMed Central Google Scholar
Pang S, Tao Z, Min X, Zhou C, Pan D, Cao Z et al (2020) Correlation between the serum platelet-derived growth factor, angiopoietin-1, and severity of coronary heart disease. Cardiol Res Pract 2020:3602608
Article PubMed PubMed Central Google Scholar
Turschner O, D’Hooge J, Dommke C, Claus P, Verbeken E, De Scheerder I et al (2004) The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J 25 9:794–803
Kleinbongard P, Heusch G (2022) A fresh look at coronary microembolization. Nat Rev Cardiol 19(4):265–280
Yaméogo NV, Guenancia C, Porot G, Stamboul K, Richard C, Gudjoncik A et al (2020) Predictors of angiographically visible distal embolization in STEMI. Herz 45(3):288–292
Galli M, Niccoli G, De Maria G, Brugaletta S, Montone RA, Vergallo R et al (2024) Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction. Nat Rev Cardiol 21(5):283–298
Article CAS PubMed Google Scholar
Caiazzo G, Musci RL, Frediani L, Umińska J, Wanha W, Filipiak KJ et al (2020) State of the art: No-Reflow phenomenon. Cardiol Clin 38 4:563–573
Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J et al (2010) Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 3(1):27–33
Mukhopadhyay S, Kumar M, Yusuf J, Gupta VK, Tyagi S (2018) Risk factors and angiographic profile of coronary slow flow (CSF) phenomenon in North Indian population: an observational study. Indian Heart J 70(3):405–409
Rao S, Bhardwaj R, Negi PC, Nath RK (2023) No reflow phenomenon in CAD patients after percutaneous coronary intervention: a prospective hospital based observational study. Indian Heart J 75(2):156–159
Article PubMed PubMed Central Google Scholar
Zhao Z, Zhang G, Yang J, Lu R, Hu H (2022) DLEU2 modulates proliferation, migration and invasion of platelet-derived growth factor-BB (PDGF-BB)-induced vascular smooth muscle cells (VSMCs) via miR-212-5p/YWHAZ axis. Cell Cycle 21(19):2013–2026
Comments (0)